[{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BI 1015550","moa":"PDE4B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BI 1015550","moa":"PDE4B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BI 1015550","moa":"PDE4B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Nerandomilast","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Nerandomilast

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : BI 1015550 (nerandomilast) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis.

Brand Name : BI 1015550

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 16, 2024

Lead Product(s) : Nerandomilast

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases (ILDs)

Brand Name : BI 1015550

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 26, 2022

Lead Product(s) : Nerandomilast

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : Patients with FVC ≥45% predicted, who were either not on antifibrotic therapy or were on a stable dose of antifibrotic therapy for at least 8 weeks before study entry, were randomized 2:1 to receive either BI 1015550 18 mg twice daily or placebo for 12...

Brand Name : BI 1015550

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 15, 2022

Lead Product(s) : Nerandomilast

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : This approval is based on results from the landmark EMPEROR-Preserved® phase III trial, which investigated the effect of empagliflozin 10 mg compared with placebo once daily, both on top of standard of care therapy, in 5,988 adults with heart failure wi...

Brand Name : BI 1015550

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 24, 2022

Lead Product(s) : Nerandomilast

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank